ArticleNanomedicine (London, England)2012
Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.
Article in Nanomedicine (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- A Dual-Pronged Hafnia-Prodrug-Lipid Nanoplatform Coupling Radiosensitization and DNA Homologous Recombination Inhibition.ACS nano medicine · 2026Article
- Intrathecal Fumagillin Alleviates Chronic Neuropathy-Induced Nociceptive Sensitization and Modulates Spinal Astrocyte-Neuronal Glycolytic and Angiogenic Proteins.Molecular neurobiology · 2025Article
- Prodrug-based nanomedicines for rheumatoid arthritis.Discover nano · 2024Review
- Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs.International journal of molecular sciences · 2019Article
- Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations.Pharmaceutics · 2019Article
- Prospects and Challenges of Phospholipid-Based Prodrugs.Pharmaceutics · 2018Article
- Cellular Trafficking of Sn-2 Phosphatidylcholine Prodrugs Studied with Fluorescence Lifetime Imaging and Super-resolution Microscopy.Precision nanomedicine · 2018Article
- Anti-angiogenic Nanotherapy Inhibits Airway Remodeling and Hyper-responsiveness of Dust Mite Triggered Asthma in the Brown Norway Rat.Theranostics · 2017Article
- Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.Molecular cancer therapeutics · 2015Article
- Angiogenesis and airway reactivity in asthmatic Brown Norway rats.Angiogenesis · 2015Article
- A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.Nanomedicine (London, England) · 2015Article
- alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.Theranostics · 2015Article
- Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide.ACS nano · 2014Article
- Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy.Advances in chronic kidney disease · 2013Review
- Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles.Biomaterials · 2012Article
- Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe chemical instability of antiangiogenic fumagillin, combined with its poor retention during intravascular transit, requires an innovative solution for clinical translation. We hypothesized that an Sn-2 lipase-labile fumagillin prodrug, in combination with a contact-facilitated drug delivery mechanism, could be used to address these problems.
methodsα(v)β(3)-targeted and nontargeted nanoparticles with and without fumagillin in the prodrug or native forms were evaluated in vitro and in vivo in the Matrigel™ (BD Biosciences, CA, USA) plug model of angiogenesis in mice.
resultsIn vitro experiments demonstrated that the new fumagillin prodrug decreased viability at least as efficacious as the parent compound, on an equimolar basis. In the Matrigel mouse angiogenesis model, α(v)β(3)-fumagillin prodrug decreased angiogenesis as measured by MRI (3T), while the neovasculature was unaffected with the control nanoparticles.
conclusionThe present approach resolved the previously intractable problems of drug instability and premature release in transit to target sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.